CN1699 Our Business - Guide for Agents
Global Medical University
Anatomy & Morphology
Anesthesia & Intensive Care
Audiology & Speech-Language Pathology
Biochemical Research Methods
Biochemistry & Molecular Biology
Biotechnology & Applied Microbiology
Cardiac & Cardiovascular Systems
Cardiovascular & Respiratory Systems
Cell & Tissue Engineering
Clinical Immunology & Infectious Disease
Clinical Psychology & Psychiatry
Critical Care Medicine
Dentistry, Oral Surgery & Medicine
Education, Scientific Disciplines
Endocrinology, Metabolism & Nutrition
Environmental Medicine & Public Health
Gastroenterology & Hepatology
General & Internal Medicine
Genetics & Heredity
Geriatrics & Gerontology
Health Care Sciences & Services
Health Policy & Services
Integrative & Complementary Medicine
Medical Laboratory Technology
Medicine, General & Internal
Medicine, Research & Experimental
Nanoscience & Nanotechnology
Nutrition & Dietetics
Obstetrics & Gynecology
Orthopedics, Rehabilitation & Sports Medicine
Peripheral Vascular Disease
Pharmacology & Pharmacy
Primary Health Care
Public Health & Health Care Science
Public, Environmental & Occupational Health
Quantum Science & Technology
Radiology, Nuclear Medicine & Imaging
Radiology, Nuclear Medicine & Medical Imaging
Research/Laboratory Medicine & Medical Technology
Social Sciences, Biomedical
Urology & Nephrology
Medrxiv - Hematology
AMERICAN JOURNAL OF HEMATOLOGY
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
BLOOD CANCER JOURNAL
BRITISH JOURNAL OF HAEMATOLOGY
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
JOURNAL OF CLINICAL APHERESIS
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
THERAPEUTIC ADVANCES IN HEMATOLOGY
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
BLOOD COAGULATION & FIBRINOLYSIS
CURRENT OPINION IN HEMATOLOGY
EUROPEAN JOURNAL OF HAEMATOLOGY
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
ASIAN JOURNAL OF TRANSFUSION SCIENCE
EGYPTIAN JOURNAL OF HAEMATOLOGY
IRAQI JOURNAL OF HEMATOLOGY
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
INTERNATIONAL JOURNAL OF HEMATOLOGY
JOURNAL OF HEMATOPATHOLOGY
[Viewpoint] COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
ACTIV-4, REMAP-CAP, and ATTACC multiplatform trials also studied therapeutic dose anticoagulation in patients with COVID-1...
[Editorial] The evolving promise and potential of gene therapy
In the first half of 2021, we have had mixed news from the field of gene therapy. March saw a halt in bluebird bio's gene ...
[Comment] CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
After 5 years of follow-up, the improved overall survival with CPX-351 versus 7+3 was maintained, which supports the previ...
[Comment] Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia
Among individuals with haemophilia, the inherited X-linked disorder caused by deficient factor VIII or factor IX and...
[Comment] Iron preparations for iron deficiency anaemia in pregnancy: which treatment is best?
Iron deficiency anaemia is a common clinical problem in pregnant women worldwide. It affects around 15–20% of women ...
[News] Newborn screening for sickle cell disease in Africa
On April 21, 2021, newborn screening for sickle cell disease was launched at Arthur Davison Children's Hospital in N...
[Correspondence] Sustained prothrombotic changes in convalescent patients with COVID-19
We read with great interest the Viewpoint by Leentjens and colleagues1Leentjens J van Haaps TF Wessels PF Schutgens REG Mi...
[In Focus] Trials and tribulations: including women in cancer clinical research
Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New ZealandDepartment of Haematol...
[Articles] Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
Background Dosing of replacement therapy with factor VIII concentrate in patients with haemophilia A...
[Articles] CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for patients with...
[Review] Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
1.Bhakta N Liu Q Ness KK et al.The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lif...
[Clinical Picture] Acute lymphoblastic leukaemia presenting as euglycaemic ketoacidosis in a patient with type 1 diabetes
A 21-year-old man presented to the Lausanne University Hospital (CHUV) in August, 2020, with reddened skin lesions o...
[Articles] Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis
1.Systemic iron homeostasis.Physiol Rev. 93: 1721-17412.Barroso F Allard S Kahan BC et al.Prevalence of maternal anaemia a...
[Comment] Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
Multiple myeloma is a malignancy of plasma cells, which is highly associated with immune suppression. Consistent with this...
[In Focus] Matthew Fowler: driving advanced nursing practice in haematology
When Matthew Fowler (consultant nurse for Oncology and Haematology, Heartlands Hospital, Birmingham, UK) first start...
[In Focus] From working in the corporate world to nursing to advocacy
Growing up, I knew exactly what I wanted to do when I finished high school. I had always pictured myself working in ...
[In Focus] Global collaboration led by the EBMT Nurses Group
The success of a haematopoietic stem-cell transplantation (HSCT) programme relies heavily on appropriately trained a...
[Editorial] Bleeding disorders: adapting to change
April 17 marked World Hemophilia Day—a day that brings the global bleeding disorders community together. The theme this ye...
[Comment] A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma
With 5 years of follow-up, A+AVD showed robust and durable improvement in progression-free survival versus ABVD, regardles...
[Comment] Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy
The treatment of multiple myeloma has evolved from being time-limited to a continuous strategy, made possible with t...
[Comment] Anti-CD25 antibody–drug conjugates: improving the delivery of death to lymphoma cells?
In The Lancet Haematology, Mehdi Hamadani and colleagues 1 Hamadani M ...
[Corrections] Correction to Lancet Haematol 2021; 8: e205–15
The DRSS is a novel risk stratification tool including disease features related to histology, genetic profile, and treatme...
[Articles] PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Background The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-gu...
[Corrections] Correction to Lancet Haematol 2021; 8: e185–93
[Articles] Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Background Lenalidomide maintenance improves progression-free survival for patients with multiple myeloma,...
[Articles] Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
Background Despite advances in the treatment of Hodgkin lymphoma with the introduction of PET-adapted ...
[Review] CAR T-cell therapy for multiple myeloma: state of the art and prospects
1.Gandhi UH Cornell RF Lakshman A et al.Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal ...
[Articles] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Intrahepatic cholestasis of pregnancy is a liver disease that slows, or even stops, the normal flow of bile to the gallbla...
[Viewpoint] Eliminating race-based reference ranges in haematology: a call to action
1.The evolution of the reference value concept.Clin Chem Lab Med. 42: 692-6972.Cheng CK Chan J Cembrowski GS van Assendelf...
Copyright © 2022 CN1699 Social. All rights reserved
Global News and Health Forum